Curative effect of adefovir dipivoxil combined with Anluohuaxian pill on hepatitis B cirrhosis

[Objective]To evaluate the efficacy of adefovir dipivoxil combined with anluohuaxian pill for early or mid-term cirrhosis due to chronic hepatitis B.[Methods]The total of 145 patients with early or mid-term hepatitis B cirrhosis were divided into control group(n=32),adefovir dipivoxil(ADV)group(n=53)and combination group(n=60).The control group was given conventional liver-protection and symptomatic treatment,the ADV group was given ADV 10mg once a day orally on the basis of conventional treatment,the combination group was given anluohuaxian pills 6 g three times a day orally on the basis of the ADV group.The course of treatment was one year.Liver function,serum liver fibrosis indices,HBV DNA levels,Child-Pugh score and portal pressure parameters of the 3 groups were compared 6 and 12 months after the treatment.[Results]The liver function of the 3 groups improved with various degree.The combination group and ADV group were more effective in improving liver function than the control group.There was statistically significant difference in albumin(ALB),globulin(GLO)between the combination group and ADV group 12 months after the treatment(P0.01).The liver fibrosis indices,HBV-DNA levels and Child-Pugh scores of the combination group and ADV group decreased more significantly than those of the control group after the treatment.The liver fibrosis indices of combination group were lower than those of ADV group.The Child-Pugh score(5.02±0.76)of the combination group was significantly lower than that(5.49±1.13) of ADV group 12 months after the treatment(P0.01).The portal vein diameter,splenic vein diameter and spleen thickness of the combination group were significantly lower than those of ADV group and the control group.The spleen thickness of ADV group reduced after the treatment(P0.05).[Conclusion]Adefovir dipivoxil combined with Anluohuaxian pill had good effect in improving liver function and reducing Child-Pugh score,liver fibrosis,portal vein pressure indicators and HBV-DNA level of early or mid-term hepatitis B cirrhosis.